20
Participants
Start Date
August 31, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
August 31, 2026
LM103
Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation and extensive expansion.
Suzhou BlueHorse Therapeutics Co., Ltd.
INDUSTRY